Research Analysts Set Expectations for ENLV Q1 Earnings

Key Points

• HC Wainwright's R. Selvaraju forecasts Q1 2027 EPS of ($0.02) and FY2027 EPS of ($0.09), and maintains a Buy rating with a $20.00 price objective.
• Analyst coverage is mixed—one Buy, one Hold and one Sell—leaving a MarketBeat consensus rating of Hold and an average target price of $16.50.
• ENLV trades around $0.83 (52‑week range $0.66–$2.10) with a market cap near $198M, and several institutions including Renaissance Technologies and Jane Street have recently increased their stakes.

Enlivex Therapeutics Ltd. (NASDAQ:ENLV - Free Report) - Investment analysts at HC Wainwright issued their Q1 2027 earnings estimates for shares of Enlivex Therapeutics in a report released on Tuesday, April 7th. HC Wainwright analyst R. Selvaraju expects that the company will earn ($0.02) per share for the quarter. HC Wainwright has a "Buy" rating and a $20.00 price objective on the stock. The consensus estimate for Enlivex Therapeutics' current full-year earnings is ($0.70) per share. HC Wainwright also issued estimates for Enlivex Therapeutics' Q2 2027 earnings at ($0.02) EPS, Q3 2027 earnings at ($0.02) EPS, Q4 2027 earnings at ($0.02) EPS and FY2027 earnings at ($0.09) EPS.

ENLV has been the subject of a number of other reports. Wall Street Zen downgraded Enlivex Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, March 28th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Enlivex Therapeutics in a research note on Monday, December 29th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $16.50.

Enlivex Therapeutics Price Performance

ENLV opened at $0.83 on Wednesday. Enlivex Therapeutics has a fifty-two week low of $0.66 and a fifty-two week high of $2.10. The business has a 50-day moving average of $1.08 and a 200-day moving average of $1.02. The company has a market capitalization of $197.83 million, a PE ratio of -1.52 and a beta of 1.68.

Institutional Investors Weigh In On Enlivex Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC lifted its holdings in Enlivex Therapeutics by 99.4% in the 4th quarter. Renaissance Technologies LLC now owns 313,628 shares of the company's stock worth $221,000 after purchasing an additional 156,336 shares during the last quarter. Citizens Financial Group Inc. RI acquired a new stake in Enlivex Therapeutics in the 3rd quarter worth approximately $241,000. HRT Financial LP lifted its holdings in Enlivex Therapeutics by 719.4% in the 4th quarter. HRT Financial LP now owns 153,990 shares of the company's stock worth $108,000 after purchasing an additional 135,198 shares during the last quarter. Jane Street Group LLC lifted its holdings in Enlivex Therapeutics by 527.4% in the 1st quarter. Jane Street Group LLC now owns 80,759 shares of the company's stock worth $78,000 after purchasing an additional 67,886 shares during the last quarter. Finally, XTX Topco Ltd lifted its holdings in Enlivex Therapeutics by 44.8% in the 4th quarter. XTX Topco Ltd now owns 61,800 shares of the company's stock worth $43,000 after purchasing an additional 19,132 shares during the last quarter. 1.02% of the stock is currently owned by institutional investors and hedge funds.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company's lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.